1. European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA Trial

2. www. Clinical trial results.org Perindopril  8 mg/day  n=6,110 Perindopril  8 mg/day  n=6,110 Placebo  n= 6,108 Placebo  n= 6,108 Endpoints (follow-up mean 3.4 years):  Primary – Composite of CV mortality, nonfatal MI, and cardiac arrest  Secondary – Composite of total death, nonfatal MI, and cardiac arrest; heart failure; revascularization (PCI/CABG); and stroke Endpoints (follow-up mean 3.4 years):  Primary – Composite of CV mortality, nonfatal MI, and cardiac arrest  Secondary – Composite of total death, nonfatal MI, and cardiac arrest; heart failure; revascularization (PCI/CABG); and stroke EUROPA Trial European Society of Cardiology 2003 12,218 low-risk patients with stable coronary artery disease Randomized, double-blind, placebo-controlled 12,218 low-risk patients with stable coronary artery disease Randomized, double-blind, placebo-controlled

3. www. Clinical trial results.org EUROPA Trial CV death/non-fatal MI/ cardiac arrest p=0.0003 European Society of Cardiology 2003 CV Mortality p=0.107

4. www. Clinical trial results.org EUROPA Trial Among patients with stable coronary artery disease, treatment with the ACE-I perindopril was associated with a reduction in the primary endpoint of cardiovascular mortality, non-fatal MI, and cardiac arrest compared with placebo ACE inhibitors have previously been shown to be effective in other patient populations, including heart failure, left ventricular dysfunction, and high-risk coronary artery disease patients The present trial is the largest to show a benefit in stable, low- risk CAD patients Among patients with stable coronary artery disease, treatment with the ACE-I perindopril was associated with a reduction in the primary endpoint of cardiovascular mortality, non-fatal MI, and cardiac arrest compared with placebo ACE inhibitors have previously been shown to be effective in other patient populations, including heart failure, left ventricular dysfunction, and high-risk coronary artery disease patients The present trial is the largest to show a benefit in stable, low- risk CAD patients